As US regulators prepare to authorise a second COVID-19 vaccine new research warns that it is likely that 25% of the world’s population will not have access to a vaccine until 2022.
The United States will authorise the Moderna vaccine in the coming days as it prepares to roll out millions of the vaccine but a study published by the BMJ warns that nearly a quarter of the world’s population has little chance of accessing the vaccine in the next 12 months.
It comes as a second study estimates that 3.7 billion adults worldwide are willing to have a covid-19 vaccine.
In the first study, researchers from the Johns Hopkins Bloomberg School of Public Health analysed pre-orders for covid-19 vaccines ahead of their regulatory approval that had been officially announced by countries around the world.
By 15 November 2020, several countries had reserved a total of 7.48 billion doses, or 3.76 billion courses from 13 manufacturers, out of 48 covid-19 vaccine candidates in clinical trials.
Just over half (51%) of these doses will go to high income countries, which represent 14% of the world’s population, say the authors. Low and middle income countries will potentially have the remainder, despite these countries comprising more than 85% of the world’s population.
It warned if all of these vaccine candidates were successfully scaled, the total projected manufacturing capacity would be 5.96 billion courses by the end of 2021, with prices ranging from $6.00 (£4.50; €4.90) per course to as high as $74 per course.
Up to 40% of the vaccine courses from these vaccine manufacturers might potentially remain for low- and middle-income countries. However, this will depend, in part, on how high-income countries share what they procure and whether the US and Russia participate in globally coordinated efforts.
But the authors point out that even if all of these vaccine manufacturers were to succeed in reaching their maximum production capacity, at least a fifth of the world’s population would not have access to vaccines until 2022.
“This study provides an overview of how high income countries have secured future supplies of covid-19 vaccines, but that access for the rest of the world is uncertain,” they write. “Governments and manufacturers might provide much needed assurances for equitable allocation of covid-19 vaccines through greater transparency and accountability over these arrangements.”
In the second study, researchers based in China and the US estimated target populations for whom vaccines would be required, to help guide development of fair and equitable allocation strategies across the globe.
They find that target population sizes for covid-19 vaccination vary widely by geographical region, vaccine objectives (such as maintaining essential core services, reducing severe covid-19, and stopping virus transmission), and the impact of vaccine hesitancy in reducing demand.
They point to evidence suggesting that around 68% of the global population (3.7 billion adults) is willing to receive a covid-19 vaccine and say their findings “provide an evidence base for global, regional, and national vaccine prioritization and allocation.”
“Variations in the size of the target populations within and between regions emphasize the tenuous balance between vaccine demand and supply, especially in low and middle income countries without sufficient capacity to meet domestic demand for covid-19 vaccine” they conclude.
Both studies are observational, and the authors acknowledge the implications of uncertainty and incomplete information for their analyses.
Nevertheless, these findings illustrate the considerable scale and complexity of manufacturing, purchasing, distributing, and administering covid-19 vaccines in a way that meets global needs, and does so equitably among nations and populations.